MARKET

PYPD

PYPD

PolyPid Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.36
-0.34
-3.18%
Closed 16:00 03/05 EST
OPEN
10.51
PREV CLOSE
10.70
HIGH
10.70
LOW
9.95
VOLUME
62.73K
TURNOVER
--
52 WEEK HIGH
19.45
52 WEEK LOW
8.64
MARKET CAP
170.13M
P/E (TTM)
-4.6583
1D
5D
1M
3M
1Y
5Y
PolyPid to Participate in Upcoming Investor Conferences
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond James 42 Annual Institution...
GlobeNewswire · 02/23 12:34
PolyPid Highlights 100th Patient Enrolled In SHIELD I Phase 3 Clinical Trial Of D-PLEX₁₀₀ For The Prevention Of Post-Abdominal Surgery Incisional Infections
Top-line Data Anticipated by Year End 2021   Enrollment Also Continues to Progress in Company's Second Phase 3 Clinical Trial, SHIELD II PETAH TIKVA, Israel, Feb. 16, 2021
Benzinga · 02/16 12:35
PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX�?��??�?? for the Prevention of Post-Abdominal Surgery Incisional Infections
PETAH TIKVA, Israel, Feb 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Top-line Data Anticipated by Year End2021 Enrollment Also Continues to Progress inCompany's...
GlobeNewswire · 02/16 12:31
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10)
Benzinga · 02/10 12:34
PolyPid reports Q4 results
PolyPid (PYPD): Q4 GAAP EPS of -$0.41.As of December 31, 2020, the Company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $66.6 million, compared to $26.6
Seekingalpha · 02/10 12:18
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three months a...
GlobeNewswire · 02/10 12:00
Polypid Ltd to Host Earnings Call
ACCESSWIRE · 02/10 11:30
The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow and follow-on offerings all served to lift stocks higher.
Benzinga · 02/06 17:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PYPD. Analyze the recent business situations of PolyPid Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PYPD stock price target is 25.80 with a high estimate of 30.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 943.21K
% Owned: 5.74%
Shares Outstanding: 16.42M
TypeInstitutionsShares
Increased
3
240.08K
New
12
164.10K
Decreased
3
74.44K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Anat Segal
Chief Executive Officer/Director
Amir Weisberg
Chief Financial Officer/Primary Contact
Shaun Marcus
Chief Operating Officer/Director
Jack Kyiet
Chief Technology Officer/Director
Noam Emanuel
No Data
About PYPD
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Webull offers kinds of Polypid Ltd stock information, including NASDAQ:PYPD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYPD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PYPD stock methods without spending real money on the virtual paper trading platform.